Pieris Pharma reports FY2022 net loss $33.3M; cash down to $59.2M; elarekibep data delayed to mid-2024

PALVELLA THERAPEUTICS, INC.

Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.
Cash, cash equivalents and investments $59.2M at Dec 31, 2022, down from $117.8M; company funded for >12 months.
Elarekibep Phase 2a asthma data now expected mid-2024; AstraZeneca adding >100 sites to complete trial.
PRS-220 Phase 1 IPF topline results expected H2 2023; PRS-400 advancing toward candidate nomination in 2023.
Seagen initiated Phase 1 for SGN-BB228, triggering $5M milestone; Servier discontinued PRS-352.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALVELLA THERAPEUTICS, INC. reported financial results for fiscal year ended December 31, 2022.

Period: fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

reported financial results for the fiscal year ended December 31, 2022, and provided a business update.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-008303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.